SGLT2 inhibitors, in particular, have been shown to slow the progression of CKD in diabetic nephropathy and may also offer protective effects on podocytes, benefiting patients with FSGS [41, 42]. The gene discussed is SLC5A2; the disease is focal segmental glomerulosclerosis.